Shopping Cart 0
Cart Subtotal
USD 0

The Global Ophthalmic Drugs Market

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 3500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 4500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Ophthalmic Drugs Market-Global Drivers, Restraints, Opportunities, Trends, and Forecast upto 2024

Overview: Ophthalmic drugs are widely used for thetreatment of eye disorders bsuch as glaucoma, conjunctivitis, cataract, dry eyes, diabetic retinopathy, and others. Development of innovative ophthalmic drugdelivery methods has aided the drug manufacturers in developing effective and advanced therapeutic tactics. American Academy of Ophthalmology has stated that, nearly 11 million individuals in the US are currectly suffering with age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinationsin eye ailments worldwide contribute to the development of the ophthalmic drugs market.

The other significant aspects that help in the improvement the market are high pervasiveness of glaucoma globally and intensification in evolution in the development of combination drugs for glaucoma. Additionally, the changing aspects in demography worldwide are driving the growth of the market. Nevertheless, a hazard of side effects related to ophthalmic drugs and loss of a patent for blockbuster drugs is hampering the market growth.

Market Analysis: The global ophthalmic drugs market is estimated to witness a CAGR of 6.3% during the forecast period 2018-2024. The global ophthalmic drugs market is analyzed based on indication type and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the ophthalmic drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 35% of the market, with a significant contribution from the US to the market growth.

Indication Type Analysis: Based on the Indication type, the market is segmented into dry eyes, glaucoma, eye infection/inflammation, retinal disorders, and others. The market is dominated by retinal disorders and is also expected to be the fastest growing segment. However, glaucoma is the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.

Key Players: Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc., and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals are the companies to watch for.

Competitive Analysis: In future, several blockbuster drugs that have dominated the more, are expected to lose their patents. The patents of successful products accounted for over USD 6 billion. The loss of patent is the most important aspect imposing major threat to the leaders in the ophthalmic drugs market., Lupin Pharmaceuticals received US FDA approval on February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan's market. Formycon AG, a German biosimilars developing company is currently developing biosimilar for Eylea by Regeneron Pharmaceuticals. Allergan, meanwhile, is under the threat from Akorn, which is developing a generic version of Restasis. The release of such product is likely to generate an strong burden on the market players.

Benefits: The report provides complete details about the usage and adoption rate of ophthalmic drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

READ MORE

Table Of Content

Scope

1 Industry Outlook 12

1.1 Industry Overview 12

1.1.1 Global Driver for Pharmaceutical Demand: 13

1.1.2 Pharmaceutical Spending Region Wise 13

1.1.3 R&D Pipeline in Pharmaceutical Industry 13

1.1.4 Top Pharma Drugs by Sales in 2017 (USD Million) 15

1.2 Industry Trends 16

1.3 Total Addressable Market 16

2 Report Outline 18

2.1 Report Scope 18

2.2 Report Summary 18

2.3 Research Methodology 19

2.4 Report Assumptions 20

3 Market Snapshot 21

3.1 Market Definition-Infoholic Research 21

3.2 Segmented Addressable Market 21

3.2.1 Trends in the Ophthalmic Drugs Market 22

3.3 Related Markets 23

3.3.1 Bacterial Conjunctivitis Drugs 23

3.3.1.1 Trends of Bacterial Conjunctivitis Drugs Market 24

3.3.2 Contact Lenses 24

3.3.2.1 Trends of contact lens market 25

4 Market Outline 27

4.1 Ophthalmic Drugs Approved by FDA 27

4.2 Market Segmentation 28

4.3 Porter 5(Five) Forces 29

4.4 PEST Analysis 30

5 Market Characteristics 31

5.1 Market Dynamics 31

5.1.1 Drivers 31

5.1.1.1 Increasing prevalence of eye diseases 31

5.1.1.2 Increasing prevalence of cataract 32

5.1.1.3 Increasing aging population 33

5.1.2 Opportunities 33

5.1.2.1 Increasing mergers & acquisitions 33

5.1.3 Restraints 34

5.1.3.1 Complex drug development process 34

5.1.3.2 Loss of patent for blockbuster drugs 34

5.2 DRO-Impact Analysis 34

5.3 Key Stakeholders 35

6 Indication: Market Size and Analysis 37

6.1 Overview 37

6.2 Dry Eyes 38

6.3 Glaucoma 39

6.4 Eye Infection/ Inflammation 40

6.5 Retinal Disorder 41

6.6 Others 42

7 Regions: Market Size and Analysis 44

7.1 Overview 44

7.2 North America 45

7.2.1 Overview 45

7.3 Europe 47

7.3.1 Overview 47

7.4 Asia Pacific 49

7.4.1 Overview 49

7.5 Rest of the World 51

7.5.1 Overview 51

8 Competitive Landscape 52

9 Vendor Profiles 54

9.1 Allergan PLC 54

9.1.1 Overview 54

9.1.2 Business Units 57

9.1.3 Geographic Revenue 58

9.1.4 Business Focus 58

9.1.5 SWOT Analysis 59

9.1.6 Business Strategies 59

9.2 Novartis AG 60

9.2.1 Overview 60

9.2.2 Business Units 64

9.2.3 Geographic Presence 65

9.2.4 Business Focus 65

9.2.5 SWOT Analysis 66

9.2.6 Business Strategy 66

9.3 Pfizer Inc. 67

9.3.1 Overview 67

9.3.2 Business Units 69

9.3.3 Geographic Presence 70

9.3.4 Business Focus 70

9.3.5 SWOT Analysis 71

9.3.6 Business Strategies 71

9.4 Valeant Pharmaceuticals International Inc. (Bausch Health) 72

9.4.1 Overview 72

9.4.2 Business Units 75

9.4.3 Geographic Presence 76

9.4.4 Business Focus 76

9.4.5 SWOT Analysis 76

9.4.6 Business Strategy 77

9.5 Santen Pharmaceutical Co., Ltd 78

9.5.1 Overview 78

9.5.2 Business Units 80

9.5.3 Geographic Presence 81

9.5.4 Business Focus 81

9.5.5 SWOT Analysis 82

9.5.6 Business Strategies 82

9.6 Akorn Inc. 83

9.6.1 Overview 83

9.6.2 Business Focus 86

9.6.3 SWOT Analysis 86

9.6.4 Business Strategy 87

9.7 Johnson & Johnson 88

9.7.1 Overview 88

9.7.2 Business Units 91

9.7.3 Geographic Revenue 92

9.7.4 Business Focus 93

9.7.5 SWOT Analysis 94

9.7.6 Business Strategies 94

10 Companies to Watch for 96

10.1 Shire plc 96

10.1.1 Overview 96

10.1.2 Highlights 97

10.2 Daiichi Sankyo, Inc. 98

10.2.1 Overview 98

10.2.2 Highlights 98

10.3 Bayer AG 99

10.3.1 Overview 99

10.4 F. Hoffmann-La Roche (Genentech) 100

10.4.1 Overview 100

10.5 Sun Pharmaceuticals 102

10.5.1 Overview 102

10.5.2 Highlights 103

Annexure 104

Abbreviations


List Of Figure

Charts

 

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 12

CHART 2 R&D INVESTMENT BY TOP 10 COMPANIES (USD BN) 13

CHART 3 CAUSES OF SIGHT LOSS GLOBALLY 16

CHART 4 RESEARCH METHODOLOGY OF GLOBAL OPHTHALMIC DRUGS MARKET 18

CHART 5 GLOBAL OPHTHALMIC DRUGS MARKET REVENUE, 2017-2024 (USD MILLION) 22

CHART 6 OVERVIEW OF GLOBAL CONTACT LENSES USER STATISTICS 24

CHART 7 OPHTHALMIC DRUGS APPROVED BY FDA DURING 2011-2017 26

CHART 8 SEGMENTATION OF GLOBAL OPHTHALMIC DRUGS MARKET 27

CHART 9 PORTER 5 FORCES OF OPHTHALMIC DRUGS MARKET 28

CHART 10 PEST ANALYSIS OF OPHTHALMIC DRUGS MARKET 29

CHART 11 MARKET DYNAMICS-DRO ANALYSIS 30

CHART 12 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%) 32

CHART 13 DRO-IMPACT ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET 33

CHART 14 KEY STAKEHOLDERS 34

CHART 15 OPHTHALMIC DRUGS MARKET BY PRODUCTS TYPE SEGMENTATION, 2017-2024 (USD MILLION) 36

CHART 16 OPHTHALMIC DRUGS MARKET REVENUE BY PRODUCTS TYPE, 2017-2024 (USD MILLION) 37

CHART 17 DRY EYES DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (USD MILLION) 37

CHART 18 GLAUCOMA DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (USD MILLION) 39

CHART 19 EYE INFECTION/ INFLAMATION DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (USD MILLION) 40

CHART 20 RETINAL DISORDER DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (USD MILLION) 41

CHART 21 OTHERS OPHTHALMIC DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (USD MILLION) 42

CHART 22 OPHTHALMIC DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%) 43

CHART 23 OPHTHALMIC DRUGS MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 44

CHART 24 OPHTHALMIC DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 46

CHART 25 OPHTHALMIC DRUGS MARKET REVENUE IN EUROPE, 2017-2024 (USD MILLION) 47

CHART 26 OPHTHALMIC DRUGS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 (USD MILLION) 49

CHART 27 OPHTHALMIC DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 50

CHART 28 ALLERGAN PLC: OFFERINGS 53

CHART 29 ALLERGAN PLC: RECENT DEVELOPMENTS 54

CHART 30 ALLERGAN PLC: OVERVIEW SNAPSHOT 55

CHART 31 ALLERGAN PLC: BUSINESS UNITS 56

CHART 32 ALLERGAN PLC: GEOGRAPHIC REVENUE 57

CHART 33 ALLERGAN PLC: SWOT ANALYSIS 58

CHART 34 NOVARTIS AG: OVERVIEW SNAPSHOT 60

CHART 35 NOVARTIS AG: BUSINESS UNITS 63

CHART 36 NOVARTIS AG: GEOGRAPHICAL PRESENCE 64

CHART 37 NOVARTIS AG: SWOT ANALYSIS 65

CHART 38 PFIZER INC.: OVERVIEW SNAPSHOT 67

CHART 39 PFIZER INC.: BUSINESS UNITS 68

CHART 40 PFIZER INC.: GEOGRAPHIC PRESENCE 69

CHART 41 PFIZER INC.: SWOT ANALYSIS 70

CHART 42 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OVERVIEW SNAPSHOT 73

CHART 43 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: BUSINESS UNITS 74

CHART 44 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL PRESENCE 75

CHART 45 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: SWOT ANALYSIS 75

CHART 46 SANTEN PHARMACEUTICAL CO., LTD: OVERVIEW SNAPSHOT 78

CHART 47 SANTEN PHARMACEUTICAL CO., LTD: BUSINESS UNITS 79

CHART 48 SANTEN PHARMACEUTICAL CO., LTD: GEOGRAPHIC PRESENCE 80

CHART 49 SANTEN PHARMACEUTICAL CO., LTD: SWOT ANALYSIS 81

CHART 50 AKORN INC.: OVERVIEW SNAPSHOT 83

CHART 51 AKORN INC.: BUSINESS UNITS 85

CHART 52 AKORN INC.: SWOT ANALYSIS 85

CHART 53 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 89

CHART 54 JOHNSON & JOHNSON: BUSINESS UNITS 90

CHART 55 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 91

CHART 56 JOHNSON & JOHNSON: SWOT ANALYSIS 93

CHART 57 SUN PHARMACEUTICALS: OVERVIEW 101

 


List Of Table

Tables

 

TABLE 1 NOVARTIS AG: OFFERINGS 60

TABLE 2 NOVARTIS AG: RECENT DEVELOPMENTS 62

TABLE 3 PFIZER INC.: OFFERINGS 68

TABLE 4 PFIZER INC.: RECENT DEVELOPMENTS 68

TABLE 5 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS 72

TABLE 6 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS 73

TABLE 7 SANTEN PHARMACEUTICAL CO., LTD: OFFERINGS 78

TABLE 8 SANTEN PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS 79

TABLE 9 AKORN INC: OFFERINGS 83

TABLE 10 AKORN INC.: RECENT DEVELOPMENTS 84

TABLE 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS 88

TABLE 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 88

TABLE 13 SHIRE PLC: OVERVIEW 96

TABLE 14 SHIRE PLC: RECENT DEVELOPMENTS 96

TABLE 15 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 98

TABLE 16 BAYER AG: OVERVIEW 99

TABLE 17 BAYER AG: RECENT DEVELOPMENTS 99

TABLE 18 F. HOFFMANN-LA ROCHE: OVERVIEW 100

TABLE 19 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 100

 

 

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc., and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals

Ophthalmic Drugs Market-Global Drivers, Restraints, Opportunities, Trends, and Forecast upto 2024

Overview: Ophthalmic drugs are widely used for thetreatment of eye disorders bsuch as glaucoma, conjunctivitis, cataract, dry eyes, diabetic retinopathy, and others. Development of innovative ophthalmic drugdelivery methods has aided the drug manufacturers in developing effective and advanced therapeutic tactics. American Academy of Ophthalmology has stated that, nearly 11 million individuals in the US are currectly suffering with age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinationsin eye ailments worldwide contribute to the development of the ophthalmic drugs market.

The other significant aspects that help in the improvement the market are high pervasiveness of glaucoma globally and intensification in evolution in the development of combination drugs for glaucoma. Additionally, the changing aspects in demography worldwide are driving the growth of the market. Nevertheless, a hazard of side effects related to ophthalmic drugs and loss of a patent for blockbuster drugs is hampering the market growth.

Market Analysis: The global ophthalmic drugs market is estimated to witness a CAGR of 6.3% during the forecast period 2018-2024. The global ophthalmic drugs market is analyzed based on indication type and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the ophthalmic drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 35% of the market, with a significant contribution from the US to the market growth.

Indication Type Analysis: Based on the Indication type, the market is segmented into dry eyes, glaucoma, eye infection/inflammation, retinal disorders, and others. The market is dominated by retinal disorders and is also expected to be the fastest growing segment. However, glaucoma is the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.

Key Players: Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc., and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals are the companies to watch for.

Competitive Analysis: In future, several blockbuster drugs that have dominated the more, are expected to lose their patents. The patents of successful products accounted for over USD 6 billion. The loss of patent is the most important aspect imposing major threat to the leaders in the ophthalmic drugs market., Lupin Pharmaceuticals received US FDA approval on February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan's market. Formycon AG, a German biosimilars developing company is currently developing biosimilar for Eylea by Regeneron Pharmaceuticals. Allergan, meanwhile, is under the threat from Akorn, which is developing a generic version of Restasis. The release of such product is likely to generate an strong burden on the market players.

Benefits: The report provides complete details about the usage and adoption rate of ophthalmic drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

READ MORE

Scope

1 Industry Outlook 12

1.1 Industry Overview 12

1.1.1 Global Driver for Pharmaceutical Demand: 13

1.1.2 Pharmaceutical Spending Region Wise 13

1.1.3 R&D Pipeline in Pharmaceutical Industry 13

1.1.4 Top Pharma Drugs by Sales in 2017 (USD Million) 15

1.2 Industry Trends 16

1.3 Total Addressable Market 16

2 Report Outline 18

2.1 Report Scope 18

2.2 Report Summary 18

2.3 Research Methodology 19

2.4 Report Assumptions 20

3 Market Snapshot 21

3.1 Market Definition-Infoholic Research 21

3.2 Segmented Addressable Market 21

3.2.1 Trends in the Ophthalmic Drugs Market 22

3.3 Related Markets 23

3.3.1 Bacterial Conjunctivitis Drugs 23

3.3.1.1 Trends of Bacterial Conjunctivitis Drugs Market 24

3.3.2 Contact Lenses 24

3.3.2.1 Trends of contact lens market 25

4 Market Outline 27

4.1 Ophthalmic Drugs Approved by FDA 27

4.2 Market Segmentation 28

4.3 Porter 5(Five) Forces 29

4.4 PEST Analysis 30

5 Market Characteristics 31

5.1 Market Dynamics 31

5.1.1 Drivers 31

5.1.1.1 Increasing prevalence of eye diseases 31

5.1.1.2 Increasing prevalence of cataract 32

5.1.1.3 Increasing aging population 33

5.1.2 Opportunities 33

5.1.2.1 Increasing mergers & acquisitions 33

5.1.3 Restraints 34

5.1.3.1 Complex drug development process 34

5.1.3.2 Loss of patent for blockbuster drugs 34

5.2 DRO-Impact Analysis 34

5.3 Key Stakeholders 35

6 Indication: Market Size and Analysis 37

6.1 Overview 37

6.2 Dry Eyes 38

6.3 Glaucoma 39

6.4 Eye Infection/ Inflammation 40

6.5 Retinal Disorder 41

6.6 Others 42

7 Regions: Market Size and Analysis 44

7.1 Overview 44

7.2 North America 45

7.2.1 Overview 45

7.3 Europe 47

7.3.1 Overview 47

7.4 Asia Pacific 49

7.4.1 Overview 49

7.5 Rest of the World 51

7.5.1 Overview 51

8 Competitive Landscape 52

9 Vendor Profiles 54

9.1 Allergan PLC 54

9.1.1 Overview 54

9.1.2 Business Units 57

9.1.3 Geographic Revenue 58

9.1.4 Business Focus 58

9.1.5 SWOT Analysis 59

9.1.6 Business Strategies 59

9.2 Novartis AG 60

9.2.1 Overview 60

9.2.2 Business Units 64

9.2.3 Geographic Presence 65

9.2.4 Business Focus 65

9.2.5 SWOT Analysis 66

9.2.6 Business Strategy 66

9.3 Pfizer Inc. 67

9.3.1 Overview 67

9.3.2 Business Units 69

9.3.3 Geographic Presence 70

9.3.4 Business Focus 70

9.3.5 SWOT Analysis 71

9.3.6 Business Strategies 71

9.4 Valeant Pharmaceuticals International Inc. (Bausch Health) 72

9.4.1 Overview 72

9.4.2 Business Units 75

9.4.3 Geographic Presence 76

9.4.4 Business Focus 76

9.4.5 SWOT Analysis 76

9.4.6 Business Strategy 77

9.5 Santen Pharmaceutical Co., Ltd 78

9.5.1 Overview 78

9.5.2 Business Units 80

9.5.3 Geographic Presence 81

9.5.4 Business Focus 81

9.5.5 SWOT Analysis 82

9.5.6 Business Strategies 82

9.6 Akorn Inc. 83

9.6.1 Overview 83

9.6.2 Business Focus 86

9.6.3 SWOT Analysis 86

9.6.4 Business Strategy 87

9.7 Johnson & Johnson 88

9.7.1 Overview 88

9.7.2 Business Units 91

9.7.3 Geographic Revenue 92

9.7.4 Business Focus 93

9.7.5 SWOT Analysis 94

9.7.6 Business Strategies 94

10 Companies to Watch for 96

10.1 Shire plc 96

10.1.1 Overview 96

10.1.2 Highlights 97

10.2 Daiichi Sankyo, Inc. 98

10.2.1 Overview 98

10.2.2 Highlights 98

10.3 Bayer AG 99

10.3.1 Overview 99

10.4 F. Hoffmann-La Roche (Genentech) 100

10.4.1 Overview 100

10.5 Sun Pharmaceuticals 102

10.5.1 Overview 102

10.5.2 Highlights 103

Annexure 104

Abbreviations


List Of Figure

Charts

 

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 12

CHART 2 R&D INVESTMENT BY TOP 10 COMPANIES (USD BN) 13

CHART 3 CAUSES OF SIGHT LOSS GLOBALLY 16

CHART 4 RESEARCH METHODOLOGY OF GLOBAL OPHTHALMIC DRUGS MARKET 18

CHART 5 GLOBAL OPHTHALMIC DRUGS MARKET REVENUE, 2017-2024 (USD MILLION) 22

CHART 6 OVERVIEW OF GLOBAL CONTACT LENSES USER STATISTICS 24

CHART 7 OPHTHALMIC DRUGS APPROVED BY FDA DURING 2011-2017 26

CHART 8 SEGMENTATION OF GLOBAL OPHTHALMIC DRUGS MARKET 27

CHART 9 PORTER 5 FORCES OF OPHTHALMIC DRUGS MARKET 28

CHART 10 PEST ANALYSIS OF OPHTHALMIC DRUGS MARKET 29

CHART 11 MARKET DYNAMICS-DRO ANALYSIS 30

CHART 12 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%) 32

CHART 13 DRO-IMPACT ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET 33

CHART 14 KEY STAKEHOLDERS 34

CHART 15 OPHTHALMIC DRUGS MARKET BY PRODUCTS TYPE SEGMENTATION, 2017-2024 (USD MILLION) 36

CHART 16 OPHTHALMIC DRUGS MARKET REVENUE BY PRODUCTS TYPE, 2017-2024 (USD MILLION) 37

CHART 17 DRY EYES DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (USD MILLION) 37

CHART 18 GLAUCOMA DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (USD MILLION) 39

CHART 19 EYE INFECTION/ INFLAMATION DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (USD MILLION) 40

CHART 20 RETINAL DISORDER DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (USD MILLION) 41

CHART 21 OTHERS OPHTHALMIC DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (USD MILLION) 42

CHART 22 OPHTHALMIC DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%) 43

CHART 23 OPHTHALMIC DRUGS MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 44

CHART 24 OPHTHALMIC DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 46

CHART 25 OPHTHALMIC DRUGS MARKET REVENUE IN EUROPE, 2017-2024 (USD MILLION) 47

CHART 26 OPHTHALMIC DRUGS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 (USD MILLION) 49

CHART 27 OPHTHALMIC DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 50

CHART 28 ALLERGAN PLC: OFFERINGS 53

CHART 29 ALLERGAN PLC: RECENT DEVELOPMENTS 54

CHART 30 ALLERGAN PLC: OVERVIEW SNAPSHOT 55

CHART 31 ALLERGAN PLC: BUSINESS UNITS 56

CHART 32 ALLERGAN PLC: GEOGRAPHIC REVENUE 57

CHART 33 ALLERGAN PLC: SWOT ANALYSIS 58

CHART 34 NOVARTIS AG: OVERVIEW SNAPSHOT 60

CHART 35 NOVARTIS AG: BUSINESS UNITS 63

CHART 36 NOVARTIS AG: GEOGRAPHICAL PRESENCE 64

CHART 37 NOVARTIS AG: SWOT ANALYSIS 65

CHART 38 PFIZER INC.: OVERVIEW SNAPSHOT 67

CHART 39 PFIZER INC.: BUSINESS UNITS 68

CHART 40 PFIZER INC.: GEOGRAPHIC PRESENCE 69

CHART 41 PFIZER INC.: SWOT ANALYSIS 70

CHART 42 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OVERVIEW SNAPSHOT 73

CHART 43 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: BUSINESS UNITS 74

CHART 44 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL PRESENCE 75

CHART 45 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: SWOT ANALYSIS 75

CHART 46 SANTEN PHARMACEUTICAL CO., LTD: OVERVIEW SNAPSHOT 78

CHART 47 SANTEN PHARMACEUTICAL CO., LTD: BUSINESS UNITS 79

CHART 48 SANTEN PHARMACEUTICAL CO., LTD: GEOGRAPHIC PRESENCE 80

CHART 49 SANTEN PHARMACEUTICAL CO., LTD: SWOT ANALYSIS 81

CHART 50 AKORN INC.: OVERVIEW SNAPSHOT 83

CHART 51 AKORN INC.: BUSINESS UNITS 85

CHART 52 AKORN INC.: SWOT ANALYSIS 85

CHART 53 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 89

CHART 54 JOHNSON & JOHNSON: BUSINESS UNITS 90

CHART 55 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 91

CHART 56 JOHNSON & JOHNSON: SWOT ANALYSIS 93

CHART 57 SUN PHARMACEUTICALS: OVERVIEW 101

 


List Of Table

Tables

 

TABLE 1 NOVARTIS AG: OFFERINGS 60

TABLE 2 NOVARTIS AG: RECENT DEVELOPMENTS 62

TABLE 3 PFIZER INC.: OFFERINGS 68

TABLE 4 PFIZER INC.: RECENT DEVELOPMENTS 68

TABLE 5 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS 72

TABLE 6 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS 73

TABLE 7 SANTEN PHARMACEUTICAL CO., LTD: OFFERINGS 78

TABLE 8 SANTEN PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS 79

TABLE 9 AKORN INC: OFFERINGS 83

TABLE 10 AKORN INC.: RECENT DEVELOPMENTS 84

TABLE 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS 88

TABLE 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 88

TABLE 13 SHIRE PLC: OVERVIEW 96

TABLE 14 SHIRE PLC: RECENT DEVELOPMENTS 96

TABLE 15 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 98

TABLE 16 BAYER AG: OVERVIEW 99

TABLE 17 BAYER AG: RECENT DEVELOPMENTS 99

TABLE 18 F. HOFFMANN-LA ROCHE: OVERVIEW 100

TABLE 19 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 100

 

 

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc., and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals

chat_bubbleLet's Chat